Gamze Özata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gamze Özata has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aida Cardona-Alberich
Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, Germany
1 shared publication Anika Bühler
Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, D-72076, Tübingen, Germany
1 shared publicationAnna Ohmayer
Werner Siemens Imaging Center, University of Tübingen
1 shared publication- Bettina Weigelin
Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany
1 shared publication Daniela Bulla-Miely
Hertie Institute for Clinical Brain Research, University of Tübingen
1 shared publication- Deborah Kronenberg-Versteeg
German Center for Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by Springer Nature in Research Square
Chimeric organotypic brain slice cultures support the maturation and functional analysis of human iPSC-derived microglia
Microglia, the primary myeloid cells of the brain, are crucial for maintaining brain homeostasis and are implicated in various neuropathological processes. Microglial identity and function are determined by their ontogeny and the brain microenvironment. Therefore, model systems that faithfully reproduce mature human microglial molecular and functional phenotypes are crucial for understanding their role in brain health and disease. Here, we demonstrate that microglial precursors derived from induced pluripotent stem cells (iPSCs) can integrate and mature in murine organotypic brain slices. Importantly, we achieve a near-complete replacement of murine with human microglia and demonstrate that their maturation is driven solely by the tissue environment through previously underappreciated cross-species human colony stimulating factor 1 receptor (hCSF1R) binding of murine interleukin 34 (IL34). The iPSC-derived microglia in the chimeric brain slice cultures (cBSCs) exhibit functional responses and develop transcriptional states reminiscent of adult human microglia while responding to developing -synuclein proteopathy with heightened inflammatory state. Thus, our findings establish cBSCs as a tool for examining human microglia in a physiologically relevant environment, while maintaining the experimental flexibility of an in vitro system for mechanistically investigating neuropathological microglial responses.
- 8 December 2025
- Published by Springer Nature in Research Square
Open AccessChimeric organotypic brain slice cultures support the maturation and functional analysis of human iPSC-derived microglia
Microglia, the primary myeloid cells of the brain, are crucial for maintaining brain homeostasis and are implicated in various neuropathological processes. Microglial identity and function are determined by their ontogeny and the brain microenvironment. Therefore, model systems that faithfully reproduce mature human microglial molecular and functional phenotypes are crucial for understanding their role in brain health and disease. Here, we demonstrate that microglial precursors derived from induced pluripotent stem cells (iPSCs) can integrate and mature in murine organotypic brain slices. Importantly, we achieve a near-complete replacement of murine with human microglia and demonstrate that their maturation is driven solely by the tissue environment through previously underappreciated cross-species human colony stimulating factor 1 receptor (hCSF1R) binding of murine interleukin 34 (IL34). The iPSC-derived microglia in the chimeric brain slice cultures (cBSCs) exhibit functional responses and develop transcriptional states reminiscent of adult human microglia while responding to developing -synuclein proteopathy with heightened inflammatory state. Thus, our findings establish cBSCs as a tool for examining human microglia in a physiologically relevant environment, while maintaining the experimental flexibility of an in vitro system for mechanistically investigating neuropathological microglial responses.
- Open Access
Multiomic profiling reveals aberrant immunomodulatory signature in β-propeller protein-associated neurodegeneration patient iPSC-derived microglia
Microglia are the primary immune cells of the central nervous system and play a crucial role in maintaining brain homeostasis. In common neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease (PD), early and sustained microglial activation has been shown to precede neuronal loss, with elevated levels of microglia-derived inflammatory mediators detected in affected brain regions. In contrast, little is known about the role of microglia in rare neurodegenerative disorders. One such disorder is β-propeller protein-associated neurodegeneration (BPAN), a common subtype of neurodegeneration with brain iron accumulation (NBIA). BPAN shares pathological features with PD, including iron accumulation and selective loss of dopaminergic neurons in the substantia nigra, and is caused by mutations in the WD repeat domain 45 (WDR45) gene encoding an autophagy protein also called WIPI4. However, the pathological role of mutant WDR45 in BPAN and the possible contribution of microglia remain unresolved. We generated the first BPAN patient microglia model system using induced pluripotent stem cells (iPSCs) to identify immune-related alterations and immunomodulatory signaling changes in a disease-relevant context. Integrated transcriptomic and proteomic profiling of iPSC-derived microglia from BPAN patients revealed a consistent shift from a homeostatic to a reactive, disease-associated state. Transcriptomic analysis showed disruption of core microglial pathways, including immune activation, stress response, and autophagy, consistent with a chronic pro-inflammatory phenotype. Complementary secretome analysis identified impaired lysosomal function and increased antigen presentation pathways, further supporting persistent microglial activation. Together this suggests that dysfunctional microglial states may contribute to BPAN pathogenesis. Our findings lay the groundwork for advancing immunomodulatory research in BPAN and may open new avenues for therapeutic development targeting microglial dysfunction.
Open AccessMultiomic profiling reveals aberrant immunomodulatory signature in β-propeller protein-associated neurodegeneration patient iPSC-derived microglia
Microglia are the primary immune cells of the central nervous system and play a crucial role in maintaining brain homeostasis. In common neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease (PD), early and sustained microglial activation has been shown to precede neuronal loss, with elevated levels of microglia-derived inflammatory mediators detected in affected brain regions. In contrast, little is known about the role of microglia in rare neurodegenerative disorders. One such disorder is β-propeller protein-associated neurodegeneration (BPAN), a common subtype of neurodegeneration with brain iron accumulation (NBIA). BPAN shares pathological features with PD, including iron accumulation and selective loss of dopaminergic neurons in the substantia nigra, and is caused by mutations in the WD repeat domain 45 (WDR45) gene encoding an autophagy protein also called WIPI4. However, the pathological role of mutant WDR45 in BPAN and the possible contribution of microglia remain unresolved. We generated the first BPAN patient microglia model system using induced pluripotent stem cells (iPSCs) to identify immune-related alterations and immunomodulatory signaling changes in a disease-relevant context. Integrated transcriptomic and proteomic profiling of iPSC-derived microglia from BPAN patients revealed a consistent shift from a homeostatic to a reactive, disease-associated state. Transcriptomic analysis showed disruption of core microglial pathways, including immune activation, stress response, and autophagy, consistent with a chronic pro-inflammatory phenotype. Complementary secretome analysis identified impaired lysosomal function and increased antigen presentation pathways, further supporting persistent microglial activation. Together this suggests that dysfunctional microglial states may contribute to BPAN pathogenesis. Our findings lay the groundwork for advancing immunomodulatory research in BPAN and may open new avenues for therapeutic development targeting microglial dysfunction.